This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ADSTILADRIN
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SUO 2024
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Conference Highlights
ASCO GU 2018
ASCO GU 2018
Prostate Cancer
Bladder Cancer
Renal Cancer
Penile, Urethral, Testicular and Adrenal Cancers
Press
ASCO GU 2018 Prostate Cancer
Viewing 1-20 of 88 articles
ASCO GU 2018: Phase II Trial of 6 Months ADT/Abiraterone Acetate Plus Prednisone and Definitive Radiotherapy - Intermediate to High Risk Localized Prostate Cancer - AbiRT Trial
ASCO GU 2018: Expression of Immune Checkpoints on Circulating Tumor Cells in Men with Metastatic Prostate CancerĀ
ASCO GU 2018: Clinical Utility of Foundation One Tissue Molecular Profiling in Men with Metastatic Prostate Cancer
ASCO GU 2018: Patterns of Progression in Bone and Soft Tissue Following Treatment with Ra-223 in Metastatic Castrate Resistant Prostate Cancer
ASCO GU 2018: Retrospective Analysis of Fatigue in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide
ASCO GU 2018: Abiraterone or Docetaxel in Men with Metastatic Castration-sensitive Prostate Cancer: A Pooled Analysis of Castration Resistance-free Survival and Toxicity
ASCO GU 2018: Real-world Study of Enzalutamide and Abiraterone Acetate (with Prednisone) Tolerability (REAAcT): Results
ASCO GU 2018: Survival Outcomes of Pre-Metastatic Castration-Resistant Prostate Cancer and the Burden of Developing Metastasis: A Systematic Literature Review
ASCO GU 2018: An Observational Study Profiling Biospecimens from 10,000 Metastatic Prostate Cancer Patients to Screen for Molecular Alterations
ASCO GU 2018: Real-World Experience with Docetaxel for Castration-Sensitive Prostate Cancer from a Population-Based Analysis
ASCO GU 2018: Best of Journals: Prostate Cancer - Medical Oncology
ASCO GU 2018: Interim analysis of a prospective randomized trial of dietary carbohydrate restriction for men with a rising PSA after failed primary treatment: Carbohydrate and Prostate Study 2
ASCO GU 2018: A phase Ib/II trial of indomethacin and enzalutamide to treat castration-resistant prostate cancer
ASCO GU 2018: Comparative Assessment of Abiraterone or Enzalutamide Activity in the PROREPAIR-B Study
ASCO GU 2018: Influence of CHAARTED, STAMPEDE, and LATITUDE eligibility criteria on utilization of abiraterone and docetaxel
ASCO GU 2018: A Phase 2 Study of Olaparib and Durvalumab in mCRPC in an Unselected Population
ASCO GU 2018: Blood-brain barrier penetration of darolutamide compared with enzalutamide using whole body autoradiography
ASCO GU 2018: Best of Journals: Prostate - Surgery
ASCO GU 2018: Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE)
ASCO GU 2018: Ability of multiparametric MRI to predict prostate tumor heterogeneity on targeted biopsy
1
2
3
4
5
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free